2型神经纤维瘤病30年随访:353例患者病程研究
基于单中心1990-2020年前瞻性数据库,评估353例符合NF2诊断标准患者的病程。中位随访期间60例(17.0%)死亡,VS手术和放疗的年均人数下降而贝伐珠单抗使用增加,无症状患者干预时间更长且生存更好,de novo体质突变者生存差于嵌合或遗传型。
要点
- NF2患者5年内43.3%需至少一次神经外科或放疗干预。
- 无症状诊断者干预时间更长且生存优于有症状者。
- de novo体质突变者生存劣于嵌合或遗传型(P=.004)。
核心结论
- 理解NF2病程有助于预后判断和更明智的护理决策。
研究设计与样本
- 单中心前瞻性数据库评估1990-2020年符合NF2诊断标准的353例患者。
- 随访至首次前庭神经鞘瘤干预和死亡,采用单因素分析并按发病年龄、转诊年代和遗传类型分层。
- 采用Cox回归分析诊断至NF2相关死亡的因素。
主要发现
- 4643.1随访年中60例(17.0%)死亡。
- VS手术年均人数从1990-1999年每100例NF2患者4.66降至2010-2020年2.11,放疗从1.65降至1.01,贝伐珠单抗使用增至2010-2020年每100例2.51。
- 153/353(43.3%)在诊断后5年内接受至少一次神经外科干预或放疗。
- 无症状诊断者干预时间更长且生存优于有症状者。
- de novo体质突变者生存劣于de novo嵌合或遗传性疾病(P=.004)。
临床怎么用
- 对无症状NF2患者可更积极观察,而有症状者需更早干预评估。
- 关注de novo体质突变患者的预后咨询和密切随访。
- 贝伐珠单抗使用增加可能改变干预模式,但需注意因肿瘤生长停药的情况。
局限性
- 单中心回顾性前瞻性数据库可能限制普遍性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist on the disease course of neurofibromatosis type 2 (NF2) to guide clinical trial design. METHODS: A prospective database of patients meeting NF2 diagnostic criteria, reviewed between 1990 and 2020, was evaluated. Follow-up to first vestibular schwannoma (VS) intervention and death was assessed by univariate analysis and stratified by age at onset, era referred, and inheritance type. Interventions for NF2-related tumors were assessed. Cox regression was performed to determine the relationship between individual factors from time of diagnosis to NF2-related death. RESULTS: Three hundred and fifty-three patients were evaluated. During 4643.1 follow-up years from diagnosis to censoring, 60 patients (17.0%) died. The annual mean number of patients undergoing VS surgery or radiotherapy declined, from 4.66 and 1.65, respectively, per 100 NF2 patients in 1990-1999 to 2.11 and 1.01 in 2010-2020, as the number receiving bevacizumab increased (2.51 per 100 NF2 patients in 2010-2020). Five patients stopped bevacizumab to remove growing meningioma or spinal schwannoma. 153/353 (43.3%) had at least one neurosurgical intervention/radiation treatment within 5 years of diagnosis. Patients asymptomatic at diagnosis had longer time to intervention and better survival compared to those presenting with symptoms. Those symptomatically presenting <16 and >40 years had poorer overall survival than those presenting at 26-39 years (P = .03 and P = .02, respectively) but those presenting between 16 and 39 had shorter time to VS intervention. Individuals with de novo constitutional variants had worse survival than those with de novo mosaic or inherited disease (P = .004). CONCLUSION: Understanding disease course improves prognostication, allowing for better-informed decisions about care.
引用
- Forde C, King AT, Rutherford SA, et al. Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol. 2021. PMID: 33336705. doi:10.1093/neuonc/noaa284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。